|Join us for a KOL Webinar, featuring David V. Sheehan MD, MBA, FACPsych, DLFAPA (University of South Florida College of Medicine) who will discuss the unmet medical needs in suicide and depression and provide insight into the existing treatment landscape.|
The discussion, moderated by Mike Moyer (LifeSci Advisors), will highlight Seelos Therapeutics’ asset SLS-002 (intranasal racemic ketamine), currently in a registration directed study for Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD).
A live question and answer session will follow the formal presentations.
If you would like to ask a question during the live Q&A, please submit your request to email@example.com
Register to attend by clicking below –
Replay Information –
For those unable to listen at this time, a replay of the call will be available by clicking
David V. Sheehan MD, MBA, FACPsych, DLFAPA, is recognized as one of the world’s leading researchers in anxiety disorders. He has written over 500 abstracts and 300 publications including a bestseller The Anxiety Disease. He has authored / edited / served on the editorial board of 11 books/monographs. Cumulatively, his publications have been cited over 50,500 times in the scientific literature. He was awarded 2 patents by the United States Patents Office. David V. Sheehan is currently Distinguished University Health Professor Emeritus at the Morsani College of Medicine, University of South Florida. Dr. Sheehan is the author, owner and copyright holder of several widely used rating scales, including the Sheehan Disability Scale (SDS), the Sheehan Irritability Scale (SIS) and the Sheehan Suicidality Tracking Scale (S-STS).
Copyright © 2023 LifeSci Advisors, LLC, All rights reserved.
250 West 55th Street, Suite 3401
New York, NY 10019
- Discovering Seelos
- Patients and Caregivers
- Investors and Media